TNFRSF17 and plasma cell myeloma: Like the NCI CAR T-cell, the biomarker soluble BCMA (sBCMA) was utilized, and three long term responders maintained low serum sBCMA concentration, indicative that this is a useful tool for myeloma progression assessment.